Open-Label Study to Evaluate Safety of A Single Dose of SYM-1219
Status:
Completed
Trial end date:
2015-10-01
Target enrollment:
Participant gender:
Summary
This is a Phase 3, multi-center, prospective, open-label study to evaluate the safety of
SYM-1219 granules containing 2 grams of secnidazole in women and postmenarchal adolescent
girls with bacterial vaginosis.